Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

KEMRI- Wellcome Trust Site Visit in Kenya

General KWTRP

Professor Jeremy Farrar, Director of the Wellcome Trust in the UK, led a review panel team to Nairobi and Kilifi in Kenya last week, to assess projects that had been ongoing over the past five years. The structural and project assessment review was conducted on Monday through to Wednesday.

CTMGH logo for News

Professor Jeremy Farrar, Director of the Wellcome Trust in the UK, led a review panel team to Nairobi and Kilifi in Kenya last week, to assess projects that had been ongoing over the past five years. The structural and project assessment review was conducted on Monday through to Wednesday.
KEMRI-Wellcome Trust in Kenya, has had high-impact research projects over the past 20 years and achieved a number of milestones in many thematic research areas including malaria public health, health systems, clinical research etc that have fed into policy change both locally and internationally.
Other members of the team who conducted the review were; Nick Rawlins, Chris Conlon, Sarah Bennet, Patrick Duffy, Simon Chaplin, Mike Turner, Mark Woolhouse, Menno De Jong among others.

Similar stories

Celebrating Women and Girls in Science

Women have made significant contribution in research despite the numerous challenges they face. To celebrate the women and girls in science we asked some women at KEMRI Wellcome Trust Research programme to share their journey in research, their achievements, and a word of advice to fellow women in science.

VAnguard Launch

KWTRP hosted the launch of the VAnguard research project. The NIHR Funded Project Builds Knowledge-base on Factors Influencing Vaccine Impact among Communities in Kenya and Uganda. The project aims to strengthen collaborations between national and international stakeholders in the identification of social and biological factors that impair vaccine impact in African communities, to develop integrated strategies and recommendations to optimize vaccine impact, and to contribute to health equity in Africa. The launch concurrently took place in Kenya and Uganda from 28th – 30th November 2022.

Oxford University named world’s top university for the 7th consecutive year

The University of Oxford has been named the best university in the world for a record seventh consecutive year in the Times Higher Education (THE) World University Rankings 2023.

Four CTMGH researchers awarded full professorships

We are delighted to announce that four of our researchers have been awarded the title of Professor, in recognition of their research achievements, contribution to teaching, and contribution to the general work of the Nuffield Department of Medicine, University of Oxford.

Quality of care, health workers’ well-being and COVID-19

Nurses are central players in the provision of quality health care globally. Although neonatal units have not been at the epicenter of the current COVID-19 pandemic, challenges have also been raised for neonatal nurses. KWTRP share their COVID-19 related experiences and challenges, highlight strategies they used to manage the challenges and show how elements of the communication skills and emotional competence course helped them cope.

High prevalence of antibodies against COVID-19 within the general population: Evidence from Nairobi and Kilifi

By May 2022, 69% of individuals residing within the Kilifi Health and Demographic System (HDSS) and 91% residing within the Nairobi Urban HDSS had evidence of an immune response to COVID-19 resulting from natural infection and/or vaccination, i.e., anti-spike IgG antibodies.